Lyra Therapeutics, Inc. (LYRA)
| Market Cap | 140.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 12.92M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $10.95 |
| Previous Close | $10.96 |
| Change ($) | -0.01 |
| Change (%) | -0.09% |
| Day's Open | 10.91 |
| Day's Range | 10.91 - 11.45 |
| Day's Volume | 16,092 |
| 52-Week Range | 9.28 - 18.56 |
LOS ANGELES--(BUSINESS WIRE)---- $LYRA #LYRA--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc.
LOS ANGELES--(BUSINESS WIRE)---- $LYRA #LYRA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc.
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Announces Positive Topline Results for LANTERN Phase 2 Randomized Controlled Study of LYR-210 for the Treatment of CRS
Lyra is to report top line data of its Phase 2 Trial in December. All indications are the trial should be a success, and they have strong backing from Perceptive Advisors.
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual London Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Appoints Nancy L. Snyderman To Its Board of Directors
Two additional presentations highlight supporting data for LYR-210’s clinical program covering key clinical endpoints for CRS and Lyra’s XTreo™ drug release performance
Three poster presentations to be featured at the 66th Annual Meeting of the American Rhinologic Society Three poster presentations to be featured at the 66th Annual Meeting of the American Rhi...
Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q2 2020 Results - Earnings Call Transcript
WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel in...
WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel in...
WATERTOWN, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel in...
Lyra Therapeutics: Advancing An Innovative Solution For Chronic Rhinosinusitis
WATERTOWN, Mass., July 07, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel in...
Lyra Therapeutics completed its IPO in late-April selling 3.5m shares at a price of $16 - the higher end of expectations - to raise $56m.
WATERTOWN, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel int...
Shares of Lyra Therapeutics Inc., a biotech specializing in treatments for ear, nose and throat diseases, soared 32% in their trading debut Friday, after the company's initial public offering ...
When a raging bull market dies and turns into a bear market with a deep recession in less than 45 days, things are not normal.
About LYRA
Lyra Therapeutics, a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was forme... [Read more...]
| Industry Biotechnology | IPO Date May 1, 2020 |
| CEO Dr. Maria Palasis Ph.D. | Employees 33 |
| Stock Exchange NASDAQ | Ticker Symbol LYRA |